MedTrace Logo

Standard Vs Adjusted Dosing of Piperacillin/Tazobactam in Acute Renal Failure and Septic Shock

NCT00816790 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2015-09-14

No results posted yet for this study

Summary

The objective of this study is to determine the feasibility of conducting a large scale randomized controlled trial comparing standard and renally adjusted dosage of antibiotics in the septic shock patients with acute renal dysfunction. We will use Piperacillin as the prototype antibiotic in our study.

Conditions

  • Septic Shock
  • Acute Renal Failure

Interventions

DRUG

Piperacillin/Tazobactam

eGFR 20-40 mls/min: Piperacillin/Tazobactam 3.375g IV q6h x 24 hours eGFR \< 20 mls/min: Piperacillin/Tazobactam 2.25g IV q6h x 24 hours

DRUG

Piperacillin/Tazobactam

Piperacillin/Tazobactam 4.5g IV q 6h x 24 hours

Sponsors & Collaborators

  • Fraser Health

    lead OTHER

Principal Investigators

  • Sean Keenan, MD · Fraser Health Authority

  • Matthew Wiens, BSc PharmD · Fraser Health Authority

  • Vincent Mabasa, BSc PharmD · Fraser Health Authority

  • Sanjiv Kangura, BSc · Fraser Health Authority

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2011-05-31
Completion
2011-06-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00816790 on ClinicalTrials.gov